Coeptis Therapeutics (NASDAQ:COEP) Stock Price Up 12.2% – What’s Next?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) shares rose 12.2% on Tuesday . The stock traded as high as $17.13 and last traded at $17.00. Approximately 77,154 shares changed hands during mid-day trading, an increase of 92% from the average daily volume of 40,114 shares. The stock had previously closed at $15.15.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Coeptis Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Coeptis Therapeutics presently has a consensus rating of “Sell”.

Coeptis Therapeutics Trading Up 12.2%

The stock has a market cap of $90.78 million, a P/E ratio of -5.18 and a beta of -0.50. The firm’s 50 day simple moving average is $15.16 and its two-hundred day simple moving average is $11.96. The company has a quick ratio of 0.83, a current ratio of 2.21 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Coeptis Therapeutics

A hedge fund recently bought a new stake in Coeptis Therapeutics stock. Yorkville Advisors Global LP bought a new stake in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 8,000 shares of the company’s stock, valued at approximately $140,000. Coeptis Therapeutics accounts for about 0.0% of Yorkville Advisors Global LP’s portfolio, making the stock its 24th largest holding. Yorkville Advisors Global LP owned 0.17% of Coeptis Therapeutics as of its most recent SEC filing. Institutional investors own 13.88% of the company’s stock.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.